Onglyza Uses
Links shared publicly online about this topic
Onglyza approved for use in renal impairment | MIMS online
mims.co.uk — “The latest pharmaceutical, medical and drugs news on MIMS online” View full resource at mims.co.uk
Most Recently Shared on March 30, 2011 at 8:46 am By:
First DPP4 inhibitor approved for use in moderate to severe renal impairment: http://www.mims.co.uk/news/1061181
FDA Approves Onglyza (saxagliptin) for Type 2 Diabetes
drugs.com — “Onglyza (saxagliptin) is used to treat Type 2 diabetes. Includes Onglyza side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on August 1, 2009 at 3:03 am By:
FDA Approves Onglyza (saxagliptin) for Type 2 Diabetes - http://bit.ly/19lKrd
Bristol, Astra's Onglyza controls diabetes: trial | Reuters
feeds.reuters.com — “LOS ANGELES (Reuters) - An interim look at a long-term study of Onglyza, under development by Bristol-Myers Squibb Co and AstraZeneca Plc, continued to show lowered glucose levels when used in combination” View full resource at feeds.reuters.com
Most Recently Shared on June 6, 2009 at 3:45 pm By:
Bristol, Astra's Onglyza controls diabetes: trial http://r.reuters.com/zyj66c
Zachary Bloomgarden, MD: the Onglyza launch | CurrentMedicine.tv
currentmedicine.tv — “Diabetes expert Zachary Bloomgarden, MD of Mount Sinai medical Center in New York discusses the newly approved DPP4-inhibtor drug, Onglyza (saxagliptin) to” View full resource at currentmedicine.tv
Most Recently Shared on October 9, 2009 at 5:18 pm By:
Healthcare Channel Health Site
Video: the new diabetes drug Onglyza launches. How will it be used? http://tinyurl.com/pfjqew
European Commission approves ONGLYZA as combination therapy with insulin for type 2 diabetes
news-medical.net — “Bristol-Myers Squibb Company and AstraZeneca today announced that the European Commission has approved ONGLYZA (saxagliptin) for use as a combination therapy with insulin (with or without metformin) to improve blood sugar (glycaemic) control in adult patients with type 2 diabetes.” View full resource at news-medical.net
Most Recently Shared on November 28, 2011 at 3:53 pm By:
Diabetes News: European Commission approves ONGLYZA as combination therapy with insulin for type 2 diabetes: Bri... http://t.co/IjDwRuPp
European Commission approves ONGLYZA as combination therapy with insulin for type 2 diabetes
news-medical.net — “Bristol-Myers Squibb Company and AstraZeneca today announced that the European Commission has approved ONGLYZA (saxagliptin) for use as a combination therapy with insulin (with or without metformin) to improve blood sugar (glycaemic) control in adult patients with type 2 diabetes.” View full resource at news-medical.net
Most Recently Shared on November 28, 2011 at 5:30 pm By:
European Commission approves ONGLYZA as combination therapy with insulin for type 2 diabetes: Bristol-Myers Squi... http://t.co/mO9KYHaO
Onglyza Becomes The First DPP4 Inhibitor Available For Use In Europe In Type 2 Diabetes Patients With Moderate Or Severe Renal Impairment
medicalnewstoday.com — “AstraZeneca and Bristol-Myers Squibb Company announced that the European Commission has approved a label update for ONGLYZA® (saxagliptin) in the treatment of adults with type 2 diabetes who h” View full resource at medicalnewstoday.com
Most Recently Shared on March 5, 2011 at 10:05 am By:
Onglyza Becomes The First DPP4 Inhibitor Available For Use In Europe In Type 2 Diabetes Patients With Moderate Or Seve... http://mnt.to/3RW4
Onglyza Becomes The First DPP4 Inhibitor Available For Use In Europe In Type 2 Diabetes Patients With Moderate Or Severe Renal Impairment
medicalnewstoday.com — “AstraZeneca and Bristol-Myers Squibb Company announced that the European Commission has approved a label update for ONGLYZA® (saxagliptin) in the treatment of adults with type 2 diabetes who h” View full resource at medicalnewstoday.com
Most Recently Shared on March 5, 2011 at 4:39 pm By:
Urology & Nephrology OW Health
Onglyza Becomes The First DPP4 Inhibitor Available For Use In Europe In Type 2 Diabetes Patients With Moderate O... http://bit.ly/gf3nof
ONGLYZA™ (Saxagliptin) U.S. Label Update Provides Further Evidence Regarding Use In Renally Impaired Adults With Type 2 Diabetes
medicalnewstoday.com — “Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration has approved the inclusion of data from two clinical studies in an u” View full resource at medicalnewstoday.com
Most Recently Shared on February 25, 2011 at 4:05 pm By:
ONGLYZA™ (Saxagliptin) U.S. Label Update Provides Further Evidence Regarding Use In Renally Impaired Adults With... http://mnt.to/3RzL
ONGLYZA™ (saxagliptin) U.S. Label Update Provides Further Evidence Regarding Use in Renally Impaired Adults with Type 2 Diabetes | Business Wire
businesswire.com — “ONGLYZA™ (SAXAGLIPTIN) U.S. LABEL UPDATE PROVIDES FURTHER EVIDENCE REGARDING USE IN RENALLY IMPAIRED ADULTS WITH TYPE 2 DIABETES” View full resource at businesswire.com
Most Recently Shared on February 23, 2011 at 1:28 pm By:
ONGLYZAâ„¢ (saxagliptin) U.S. Label Update Provides Further Evidence Regarding Use in Renally Impaired Adults with... http://bit.ly/gSh9uj
ONGLYZA™ (Saxagliptin) U.S. Label Update Provides Further Evidence Regarding Use In Renally Impaired Adults With Type 2 Diabetes | Diabetes | Type 2 Diabetes | Diabetes Mellitus | Keyvive.com
keyvive.com — “ONGLYZA™ (Saxagliptin) U.S. Label Update Provides Further Evidence Regarding Use In Renally Impaired Adults With Type 2 Diabetes | Diabetes | Type 2 Diabetes | Diabetes Mellitus | Keyvive.com” View full resource at keyvive.com
Most Recently Shared on February 28, 2011 at 5:09 pm By:
ONGLYZA™ (Saxagliptin) U.S. Label Update Provides Further Evidence Regarding Use In Renally… http://goo.gl/fb/nJSP7
Saxagliptin approved for diabetic patients
theheart.org — “The FDA has approved once-daily saxagliptin tablets for use with diet and exercise to control hyperglycemia in patients with type2 diabetes mellitus.” View full resource at theheart.org
Most Recently Shared on August 3, 2009 at 5:44 pm By:
heartwire: Saxagliptin approved to improve glycemic control in diabetic patients http://bit.ly/WoT7T
Bristol-Myers Squibb: Press Releases
bms.com — “Bristol-Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines that help patients prevail over serious diseases.” View full resource at bms.com
Most Recently Shared on November 28, 2011 at 6:02 pm By:
ONGLYZA® (saxagliptin) Approved for Use in Europe as Combination Therapy With Insulin for T2D (BMS) http://t.co/rB8yZIk3
DPP-4 Inhibitors :: Diabetes Self-Management
diabetesselfmanagement.com — “In 2006, a new class of medicine for Type 2 diabetes was introduced to the U.S. market. Called DPP-4 inhibitors, these drugs work in a way that is different from any previous diabetes treatment. Sitagliptin (brand name Januvia) is the first drug in this class to be approved; it can be used alone or in combination with other oral diabetes drugs. Saxagliptin (Onglyza), another DPP-4 inhibitor, received approval in August 2009...” View full resource at diabetesselfmanagement.com
Most Recently Shared on August 12, 2009 at 7:05 pm By:
Diabetes Self-Mgmt Health Site
#diabetes Article of the Week: DPP-4 Inhibitors: A Novel Class of Drugs for Type 2 Diabetes http://bit.ly/19Q8o8
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
MIMS Online
MIMS is the print and online prescribing database for all healthcare professionals.
-
Drugs.com
Keeping you up to date with the latest medication news, FDA Medwatch alerts and new drug approvals.
-
Reuters Health
Advertisement
